Brought to you by 
Pfizer buys Vicuron for $1.9bn in cash
06 Oct 2005
Executive Summary
In a deal worth $1.9bn, Pfizer has agreed to purchase all the outstanding shares of Vicuron Pharmaceuticals (therapeutics for hospital-based and community-acquired infections) for $29.10 per share, an 80% premium to market.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Pfizer buys Vicuron for $1.9bn in cash
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice